Table 4.
Pooled estimates with 95 % confidence interval for prevalence, sensitivity and specificity
| Study population | Comparator to liver biopsy | Liver fibrosis per stage | No. of studies | Prevalence [% (95 % CI)] | Sensitivity [% (95 % CI)] | Specificity [% (95 % CI)] |
|---|---|---|---|---|---|---|
| B | VTq | F ≥ 2 | 2 | 43 (6–79) | 70 (32–92) | 87 (79–92) |
| F4 | 1 | 27 (19–36) | 93 (77–99) | 77 (66–86) | ||
| TE | F ≥ 2 | 1 | 61 (51–70) | 82 (70–90) | 71 (55–84) | |
| F4 | 1 | 27 (19–36) | 88 (73–98) | 87 (78–94) | ||
| C | VTq | F ≥ 1 | 2 | 91 (83–95) | 70 (67–73) | 81 (70–88) |
| F ≥ 2 | 5 | 60 (48–71) | 78 (70–85) | 79 (73–84) | ||
| F ≥ 3 | 5 | 40 (32–48) | 86 (76–92) | 84 (81–88) | ||
| F4 | 4 | 23 (18–29) | 85 (80–88) | 81 (75–86) | ||
| TE | F ≥ 2 | 1 | 63 (54–71) | 71 (61–80) | 71 (57–83) | |
| F ≥ 3 | 1 | 39 (31–47) | 77 (64–80) | 85 (75–92) | ||
| F4 | 1 | 22 (15–29) | 70 (51–85) | 82 (73–88) | ||
| B and C | VTq | F ≥ 2 | 7 | 55 (42–67) | 77 (69–84) | 81 (76–85) |
| F4 | 5 | 23 (18–29) | 85 (81–89) | 80 (76–85) | ||
| TE | F ≥ 2 | 2 | 62 (53–70) | 76 (64–85) | 71 (61–79) | |
| F4 | 2 | 23 (14–36) | 79 (56–92) | 84 (78–88) |
Each subgroup is classified as separate study
CI confidence interval, TE transient elastography, VTq Virtual Touch™ Quantification